Clinical Trial Search

Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05

Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale

Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants

Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12

Primary: Percent of Participants That Complete the Hypnotherapy Program — 22 Participants

Primary: Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score — -9.54; -9.17 units on a scale

Primary: Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry — 241.9; 340.4 mm Hg

Primary: Patient's Evaluation of Symptomatic Improvement by Overall Treatment Efficacy (OTE) — 1; 5; 13; 18 Participants — p=0.038

Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06

Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants

Primary: Changes in Severity of Functional Dyspepsia Symptoms — 10.1; 10.0; 5.1; 5.2 score on a scale — p=0.041

Primary: Rate of Complete Dyspepsia Symptom Relief — 22.4; 29.3; 27.0; 17.9 Percentage of Participants

Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes

Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6

Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL

Primary: Frequency of Contractions at Baseline — 20; 24.6; 23.7 stomach contractions/minute

Primary: Subjective Symptom Improvement Rate — 75.7; 73.5; 68.6; 65.3 percentage of participants

Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003

Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants

Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants

Primary: Percentage of "Responders" to Duspatalin® Therapy — 63.6; 36.4 percentage of participants

Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours

Primary: Change in GERD Symptoms — 0.6; -1.7 units on a scale — p=0.41

Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day

Primary: Number of Gastroesophageal Refluxes — 42.4 refluxes — p=0.000002

Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78

Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879

Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69

Primary: Rumination Score (Self-perceived Rumination Frequency) — 4 score on a scale — p=0.005

Primary: The Primary Outcome Measure Was Mean Daily Pain — 39.9; 45.14 pain scale by VAS in mm — p=<0.03